Board of Directors
 |
Fuminori Yoshida Fuminori Yoshida graduated from Gakushuin University in 1971 with a B.S. in Organic Chemistry. He went on to receive an M.S. in Molecular Biology from MIT and an M.S. in Health Policy and Management from Harvard University Graduate School. After working for Mitsubishi Corporation and AHS Japan, he founded Nippon Bio-Rad Laboratories in 1980, serving as President. He subsequently served as President and CEO of Syntex Japan from 1991, and as President and CEO of Amgen K.K. (Japan) and Corporate Vice President of Amgen Inc. from 1993. After leaving Amgen in January 2005, he founded SymBio Pharmaceuticals Limited in March 2005, and assumed the position of Representative Director, President and CEO. |
|---|---|
 |
Hiroshi Nomura Hiroshi Nomura joined Sumitomo Chemical Co., Ltd. (currently Sumitomo Chemical Company, Limited) in 1981. He was seconded to Sumitomo Pharmaceuticals Co., Ltd. in 2003, and transferred to Dainippon Sumitomo Pharma Co., Ltd. (currently Sumitomo Pharma Co., Ltd.) in 2008, where he became Executive Officer in the same year. After serving as Member of the Board of Directors and Executive Officer in 2012, Member of the Board of Directors and Managing Executive Officer in 2014, and Member of the Board of Directors and Senior Managing Executive Officer in 2016, he was appointed Representative Director and Senior Managing Executive Officer in 2017, and Representative Director, President and CEO in 2018. He served as Special Advisor to the company in 2024, and Honorary Advisor in 2025. In March 2026, he was appointed to serve as Director (Outside) of the Company. |
 |
Bruce David Cheson Dr. Bruce David Cheson received his medical degree from Tufts University and completed his residency at University of Virginia Hospitals in 1971 and fellowship at New England Medical Center Hospital in 1974. He then assumed Assistant Professor of Medicine, Hematology/Oncology of University of Utah School, University of Utah Hospital in 1977, and Senior Investigator and Head of Medicine Section, National Cancer Institute, Cancer Therapy Evaluation Program in 1984. Scientific Advisor to the Lymphoma Research Foundation in 2001. He joined Georgetown University Hospital, Lombardi Comprehensive Cancer Center as Deputy Chief, Hematology-Oncology, Head of Hematology in 2002. He served as an external director of the board at Morphosys in 2016, and became Frank M. Ewing Foundation Chair in Hematology-Oncology in 2018. He was appointed to serve as Director (Outside) of the Company in March 2019. He became a physician at the Center for Cancer and Blood Disorders in 2021, and a Lymphoma Consultant in 2025. |
 |
George Morstyn Dr. George Morstyn has more than 25 years' experience in the biotechnology industry including as Senior Vice President of Development and Chief Medical Officer at Amgen where he had overall responsibility globally for drug development in all therapeutic areas. Prior to joining Amgen, he was principal investigator on the earliest clinical studies of the haemopoietic colony stimulating factors. From 2010 to 2016 he was Deputy Chairman of the Victorian Comprehensive Cancer Centre. He served as the Chief Executive Officer of G & R Morstyn Pty Ltd., and a non-executive director of Actinogen (ASX listed) and PioTx (Australia). He served as a Director (Outside) of SymBio from 2009 to 2019, and was appointed as the Chair of the Scientific Advisory Board of the Company in 2019. In March 2024, he was appointed to serve as Director (Outside) of the Company. |
 |
Ralph Smalling Ralph Smalling received a B.A. in Biology from Occidental College in 1977, and an M.S. in Microbiology from California State University in 1981. He joined Amgen, Inc. in 1982, and served as Vice President of Regulatory Affairs and International Clinical Safety and Vice President of Global R&D Policy and Analysis. In 1997, he was an integral part of the industry team that negotiated renewal of the Prescription Drug User Act (PDUFA II). He authored several provisions of the Food Drug and Administration Modernization Act (FDAMA) passed by Congress the same year. He serves as Vice President of Regulatory Affairs at Genelux Corporation in the U.S. (2023 - present), and provides consulting services to other clients. In March 2025, he was appointed to serve as Director (Outside) of the Company. |
 |
Koichi Shimomura Koichi Shimomura graduated from Hitotsubashi University with a degree in sociology in 1982 and joined Japan Petroleum Exploration Co., Ltd. ("JAPEX") in the same year. He mainly worked in the Overseas Business Division and served as General Manager of Media and Investors Relations from 2006. Moreover, he was appointed as a full-time auditor of JAPEX in 2018, then served as a full-time auditor of Japex Offshore Ltd., a subsidiary of JAPEX in 2022. He also served as General Manager of the Legal Department of HW ELECTRO Co., Ltd. in 2024. He was appointed as Director, Audit & Supervisory Committee Member (Outside) of the Company in March 2025. In March 2026, he was appointed to serve as Director, Full-Time Audit & Supervisory Committee Member (Outside) of the Company. |
|
Eiji Mizutani Eiji Mizutani joined Shinwa Audit Corporation (currently KPMG AZSA LLC) in 1981 and registered as a Certified Public Accountant in 1985. He became a Partner at the firm in 2003, and subsequently served as a Board Member in 2010, Head of Quality Management Department in 2014, and Chairman of the Senior Review Board in 2015. He was appointed as an Outside Audit & Supervisory Board Member of J-Oil Mills, Inc. in 2021. He also served as Head of the Eiji Mizutani CPA Office in the same year. He was appointed as an Outside Audit & Supervisory Board Member of Obayashi Corporation in 2022. In March 2026, he was appointed to serve as Director, Audit & Supervisory Committee Member (Outside) of the Company. |
|
Tsuyoshi Ichinosawa Tsuyoshi Ichinosawa joined KPMG AZSA LLC in 2004 and registered as a Certified Public Accountant in 2008. In 2014, he registered as an Attorney at Law and joined Ogasawara Rokugawa Sogo Law Office. After working at Hanzomon Sogo Law Office from 2015, he joined Ichinosawa Law Office in 2017. He served as an Outside Audit & Supervisory Board Member of SOLBRAIN Co., Ltd. and as a Part-time Lecturer at the Headquarters for International Industry-University Collaboration, University of Tsukuba in 2020. In 2022, he was appointed as an Outside Director of Fines Inc. and as Chairman of its Nomination and Remuneration Committee. Furthermore, he served as a Part-time Audit & Supervisory Board Member of GMO OMAKASE, Inc. and Albirex Niigata, Inc. in 2023. In March 2026, he was appointed to serve as Director, Audit & Supervisory Committee Member (Outside) of the Company. |